| Literature DB >> 29536006 |
Reinier Snetselaar1, Matthijs F M van Oosterhout2, Jan C Grutters1,3, Coline H M van Moorsel1,3.
Abstract
The enzyme telomerase reverse transcriptase (TERT) is essential for telomere maintenance. In replicating cells, maintenance of telomere length is important for the preservation of vital genetic information and prevention of genomic instability. A common genetic variant in TERT, rs2736100 C/A, is associated with both telomere length and multiple diseases. Carriage of the C allele is associated with longer telomere length, while carriage of the A allele is associated with shorter telomere length. Furthermore, some diseases have a positive association with the C and some with the A allele. In this study, meta-analyses were performed for two groups of diseases, cancerous diseases, e.g., lung cancer and non-cancerous diseases, e.g., pulmonary fibrosis, using data from genome-wide association studies and case-control studies. In the meta-analysis it was found that cancer positively associated with the C allele (pooled OR 1.16 [95% CI 1.09-1.23]) and non-cancerous diseases negatively associated with the C allele (pooled OR 0.81 [95% CI 0.65-0.99]). This observation illustrates that the ambiguous role of telomere maintenance in disease hinges, at least in part, on a single locus in telomerase genes. The dual role of this single nucleotide polymorphism also emphasizes that therapeutic agents aimed at influencing telomere maintenance should be used with caution.Entities:
Keywords: cancer; degenerative disease; single nucleotide polymorphism; telomerase; telomere
Year: 2018 PMID: 29536006 PMCID: PMC5835035 DOI: 10.3389/fmed.2018.00041
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1Flowchart of studies included in the meta-analysis.
Studies included in the meta-analyses.
| Association rs2736100_C | |||||
|---|---|---|---|---|---|
| Study | Cases | Controls | Odds ratio | 95% CI | Disease |
| ( | 245 | 489 | 1.12 | 0.90–1.39 | Pediatric brain tumor |
| ( | 445 | 497 | 1.29 | 1.07–1.55 | Lung cancer |
| ( | 1,154 | 1,137 | 1.24 | 1.10–1.39 | Lung cancer |
| ( | 1,896 | 1,939 | 1.13 | 1.03–1.24 | Pancreatic cancer |
| ( | 1,094 | 1,100 | 1.14 | 1.01–1.30 | Lung cancer |
| ( | 4,441 | 5,194 | 1.22 | 1.15–1.29 | Lung cancer |
| ( | 5,550 | 7,585 | 0.91 | 0.99–0.84 | Pancreatic cancer |
| ( | 976 | 1,057 | 1.26 | 1.11–1.43 | Glioma |
| ( | 196 | 229 | 1.65 | 1.17–2.32 | Lung cancer |
| ( | 13,265 | 40,245 | 1.08 | 1.12–1.04 | Endometrial cancer |
| ( | 243 | 246 | 1.20 | 0.92–1.55 | Gastric cancer |
| ( | 386 | 587 | 0.94 | 0.78–1.14 | Liver cancer |
| ( | 22,233 | 64,762 | 0.77 | 0.50–1.17 | Coronary artery disease |
| ( | 663 | 420 | 0.99 | 0.79–1.25 | Renal cell carcinoma |
| ( | 845 | 1,190 | 1.27 | 1.12–1.44 | Glioma |
| ( | 1,514 | 2,470 | 1.01 | 0.92–1.10 | Coronary artery disease |
| ( | 1,136 | 1,012 | 1.02 | 0.90–1.15 | Gastric cancer |
| ( | 639 | 649 | 1.37 | 1.18–1.61 | Glioma |
| ( | 3,131 | 3,702 | 1.02 | 0.94–1.11 | Skin cancer |
| ( | 84 | 257 | 1.15 | 0.81–1.63 | Arteriosclerosis |
| ( | 2,477 | 6,550 | 0.73 | 0.68–0.78 | Pulmonary fibrosis |
| ( | 970 | 525 | 1.17 | 1.04–1.33 | Bladder cancer |
| ( | 510 | 913 | 1.17 | 1.00–1.37 | Skin cancer |
| ( | 3,264 | 1,793 | 0.98 | 0.77–1.25 | Colorectal cancer |
| ( | 2,308 | 2,321 | 1.48 | 1.36–1.62 | Lung cancer |
| ( | 8,559 | 9,378 | 1.25 | 1.20–1.31 | Lung cancer |
| ( | 1,145 | 1,142 | 0.96 | 0.78–1.17 | Breast cancer |
| ( | 716 | 716 | 1.17 | 1.00–1.38 | Lung cancer |
| ( | 717 | 202 | 1.57 | 1.25–1.96 | Myeloproliferative neoplasms |
| ( | 104 | 135 | 1.01 | 0.70–1.46 | Colorectal cancer |
| ( | 855 | 844 | 1.16 | 1.02–1.33 | Lung cancer |
| ( | 1,212 | 1,339 | 1.14 | 1.02–2.27 | Lung cancer |
| ( | 349 | 914 | 0.81 | 0.68–0.97 | Testicular cancer |
| ( | 16,039 | 16,430 | 0.93 | 0.91–0.96 | Colorectal cancer |
| ( | 370 | 1,173 | 1.38 | 1.23–1.56 | Lung cancer |
| ( | 584 | 400 | 1.77 | 1.47–2.12 | Myeloproliferative neoplasms |
| ( | 518 | 1,201 | 1.64 | 1.42–1.91 | Glioma |
| ( | 855 | 1,160 | 1.16 | 1.01–1.33 | Glioma |
| ( | 4,543 | 5,505 | 1.38 | 1.31–1.47 | Lung cancer |
| ( | 193 | 197 | 1.29 | 1.00–1.67 | Lung cancer |
| ( | 5,739 | 5,848 | 1.09 | 1.03–1.15 | Lung cancer |
| ( | 370 | 1,263 | 1.10 | 0.93–1.29 | Colorectal cancer |
| ( | 2,283 | 2,785 | 1.18 | 1.09–1.27 | Lung cancer |
| ( | 304 | 319 | 1.33 | 1.06–1.67 | Lung cancer |
| ( | 690 | 1,538 | 1.19 | 1.03–1.38 | Bladder cancer |
| ( | 5,457 | 4,493 | 1.38 | 1.30–1.47 | Lung cancer |
| ( | 5,870 | 9,319 | 1.14 | 1.08–1.20 | Lung cancer |
| ( | 2,086 | 11,034 | 1.27 | 1.19–1.37 | Lung cancer |
| ( | 226 | 806 | 1.22 | 0.99–1.51 | Acute myeloid leukemia |
| ( | 226 | 806 | 1.44 | 1.10–1.88 | Glioma |
| ( | 242 | 1,496 | 0.55 | 0.45–0.68 | Idiopathic pulmonary fibrosis |
| ( | 352 | 447 | 1.18 | 0.97–1.45 | Lung cancer |
| ( | 277 | 831 | 1.19 | 1.04–1.37 | Skin cancer |
| ( | 1,681 | 1,635 | 1.16 | 1.04–1.30 | Lung cancer |
| ( | 3,534 | 4,098 | 1.08 | 1.02–1.16 | Breast cancer |
| ( | 1,955 | 1,995 | 1.11 | 1.00–1.23 | Pancreatic cancer |
| ( | 596 | 1,480 | 1.08 | 0.94–1.23 | Endometrial cancer |
| ( | 1,854 | 4,949 | 1.30 | 1.19–1.41 | Glioma |
| ( | 810 | 3,080 | 1.23 | 1.10–1.37 | Glioma |
| ( | 1,029 | 1,668 | 1.31 | 1.17–1.47 | Glioma |
| ( | 660 | 523 | 0.92 | 0.78–1.09 | Breast cancer |
| ( | 372 | 363 | 0.95 | 0.77–1.16 | Prostate cancer |
| ( | 569 | 656 | 1.23 | 1.05–1.45 | Acute lymphoblastic leukemia |
| ( | 1,878 | 3,670 | 1.27 | 1.19–1.37 | Glioma |
| ( | 5,992 | 13,531 | 1.34 | 1.28–1.41 | Lung cancer |
| ( | 807 | 708 | 1.24 | 1.05–1.48 | Lung cancer |
| ( | 810 | 4,479 | 1.31 | 1.16–1.48 | Myeloproliferative neoplasms |
| ( | 719 | 6,030 | 1.08 | 0.97–1.21 | Lung cancer |
| ( | 10,812 | 13,913 | 1.15 | 1.10–1.20 | Lung cancer |
| ( | 661 | 1,347 | 1.32 | 1.14–1.52 | Lung cancer |
| ( | 1,045 | 8,403 | 0.75 | 0.67–0.85 | Testicular cancer |
| ( | 1,660 | 1,299 | 1.39 | 1.28–1.50 | Glioma |
| ( | 1,618 | 7,736 | 1.39 | 1.28–1.50 | Glioma |
| ( | 239 | 553 | 1.30 | 1.04–1.61 | Lung cancer |
| ( | 1,033 | 1,053 | 1.16 | 1.03–1.32 | Cervical cancer |
| ( | 1,552 | 1,605 | 1.20 | 1.09–1.33 | Lung cancer |
| ( | 370 | 686 | 0.78 | 0.63–0.96 | Interstitial lung disease |
| ( | 1,404 | 5,040 | 1.24 | 1.10–1.39 | Lung cancer |
| ( | 239 | 1,197 | 0.89 | 0.73–1.08 | Depression |
| ( | 692 | 3,992 | 1.51 | 1.35–1.71 | Glioma |
| ( | 580 | 580 | 0.81 | 0.69–0.95 | Male infertility |
| ( | 1,735 | 1,036 | 1.11 | 0.99–1.24 | Lung cancer |
| ( | 524 | 524 | 1.34 | 1.13–1.60 | Lung cancer |
| ( | 1,425 | 3,011 | 1.26 | 1.11–1.43 | Lung cancer |
| ( | 784 | 782 | 1.28 | 1.11–1.47 | Lung cancer |
| ( | 2,096 | 2,147 | 1.38 | 1.27–1.51 | Esophageal cancer |
Figure 2Meta-analysis of non-cancer association to rs2736100 allele C. OR, odds ratio; 95% CI, 95% confidence interval.
Figure 3Meta-analysis of cancer association to rs2736100 allele C. OR, odds ratio; 95% CI, 95% confidence interval.
Figure 4Overall association of the cancer and age-related group of diseases with telomerase reverse transcriptase rs2736100 allele C. OR, odds ratio; 95% CI, 95% confidence interval.
Figure 5Evaluation of (publication) bias for the cancer (A) and non-cancer (B) meta-analysis. LFK index, Luis Furuya-Kanamori index; OR, odds ratio.